4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline

Identification

Generic Name
4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline
DrugBank Accession Number
DB03365
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 297.3086
Monoisotopic: 297.111341361
Chemical Formula
C16H15N3O3
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UCyclin-dependent kinase 2Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazanaphthalenes
Sub Class
Benzodiazines
Direct Parent
Quinazolinamines
Alternative Parents
m-Aminophenols / Anisoles / Aniline and substituted anilines / Aminopyrimidines and derivatives / Alkyl aryl ethers / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Imidolactams / Heteroaromatic compounds / Secondary amines
show 3 more
Substituents
1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / Alkyl aryl ether / Amine / Aminophenol / Aminopyrimidine / Aniline or substituted anilines / Anisole / Aromatic heteropolycyclic compound / Azacycle
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available
InChI Key
BNDYIYYKEIXHNK-UHFFFAOYSA-N
InChI
InChI=1S/C16H15N3O3/c1-21-14-7-12-13(8-15(14)22-2)17-9-18-16(12)19-10-4-3-5-11(20)6-10/h3-9,20H,1-2H3,(H,17,18,19)
IUPAC Name
3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol
SMILES
COC1=CC2=NC=NC(NC3=CC(O)=CC=C3)=C2C=C1OC

References

General References
Not Available
PubChem Compound
5687
PubChem Substance
46508544
ChemSpider
5485
BindingDB
4622
ChEMBL
CHEMBL127907
ZINC
ZINC000003828650
PDBe Ligand
DTQ
PDB Entries
1di8 / 3nyv / 4btk / 5amn / 6u0k

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.133 mg/mLALOGPS
logP3.1ALOGPS
logP2.84Chemaxon
logS-3.4ALOGPS
pKa (Strongest Acidic)9.67Chemaxon
pKa (Strongest Basic)4.65Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area76.5 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity82.51 m3·mol-1Chemaxon
Polarizability31.05 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9309
Blood Brain Barrier+0.6708
Caco-2 permeable+0.6161
P-glycoprotein substrateNon-substrate0.5397
P-glycoprotein inhibitor INon-inhibitor0.7113
P-glycoprotein inhibitor IINon-inhibitor0.601
Renal organic cation transporterNon-inhibitor0.891
CYP450 2C9 substrateNon-substrate0.7634
CYP450 2D6 substrateNon-substrate0.844
CYP450 3A4 substrateNon-substrate0.5736
CYP450 1A2 substrateInhibitor0.5905
CYP450 2C9 inhibitorNon-inhibitor0.6128
CYP450 2D6 inhibitorNon-inhibitor0.613
CYP450 2C19 inhibitorInhibitor0.6788
CYP450 3A4 inhibitorNon-inhibitor0.5479
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7337
Ames testAMES toxic0.8446
CarcinogenicityNon-carcinogens0.9428
BiodegradationNot ready biodegradable0.9925
Rat acute toxicity2.3855 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9684
hERG inhibition (predictor II)Non-inhibitor0.6263
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-107i-0390000000-864161d0a3af5311f1b0
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-0490000000-45e9bedef760824b25f5
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-0090000000-c6e3288e9f18a720d44e
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-0090000000-4b6e88ac0f4e77520282
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-0090000000-b455898e1e8e237338ea
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0f89-0290000000-4e1ded8922e49408c81b
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0290000000-1703d87f045b4cf8b3f3
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-166.96205
predicted
DeepCCS 1.0 (2019)
[M+H]+169.32002
predicted
DeepCCS 1.0 (2019)
[M+Na]+175.41318
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details
1. Cyclin-dependent kinase 2
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, N...
Gene Name
CDK2
Uniprot ID
P24941
Uniprot Name
Cyclin-dependent kinase 2
Molecular Weight
33929.215 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52